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Hepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high
mortality without treatment. Terlipressin with albumin is effective in the reversal of HRS.
Where terlipressin is not available, as in the United States, midodrine and octreotide with
albumin are used as an alternative treatment of HRS. The aim was to compare the effec-
tiveness of terlipressin plus albumin versus midodrine and octreotide plus albumin in the
treatment of HRS in a randomized controlled trial. Twenty-seven patients were randomized
to receive terlipressin with albumin (TERLI group) and 22 to receive midodrine and
octreotide plus albumin (MID/OCT group). The TERLI group received terlipressin by
intravenous infusion, initially 3 mg/24 hours, progressively increased to 12 mg/24 hours if
there was no response. The MID/OCT group received midodrine orally at an initial dose
of 7.5 mg thrice daily, with the dose increased to a maximum of 12.5 mg thrice daily,
together with octreotide subcutaneously: initial dose 100 lg thrice daily and up to 200 lg
thrice daily. Both groups received albumin intravenously 1 g/kg of body weight on day 1
and 20-40 g/day thereafter. There was a significantly higher rate of recovery of renal func-
tion in the TERLI group (19/27, 70.4%) compared to the MID/OCT group (6/21,
28.6%), P5 0.01. Improvement in renal function and lower baseline Model for End-Stage
Liver Disease score were associated with better survival. Conclusion: Terlipressin plus albu-
min is significantly more effective than midodrine and octreotide plus albumin in improv-
ing renal function in patients with HRS (HEPATOLOGY 2015;62:567-574)
See Editorial on Page 352
Hepatorenal syndrome (HRS) is a potentiallyreversible form of renal failure that occurs inpatients with cirrhosis and ascites.1-4 Accord-
ing to the peripheral arterial vasodilatation hypothesis,5
HRS is caused by severe renal arterial vasoconstriction
in response to reduction in the effective circulating
volume. Renal vasoconstriction is mediated by the
renin-angiotensin and sympathetic nervous systems
and the nonosmotic release of vasopressin. The reduc-
tion in the effective circulating volume is a conse-
quence of marked splanchnic arterial vasodilatation
and low cardiac output. Bacterial infections precipitate
HRS by increasing vasodilatation and worsening the
cardiocirculatory dysfunction of cirrhosis. There are
two types of HRS. Type 1 HRS is characterized by
rapid progressive renal failure defined by doubling of
the initial serum creatinine concentrations to a level
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greater than 226 lmol/L (2.5 mg/dL) in less than 2
weeks. Type 2 HRS is characterized by moderate renal
failure (serum creatinine 133-226 lmol/L or 1.5-
2.5 mg/dL), with a steady or slowly progressive
course.4
Median survival in untreated patients with HRS
may be as short as 2 weeks; liver transplantation is the
treatment of choice.6 However, patients with HRS
have a high mortality rate while awaiting transplant.
Moreover, post–liver transplant survival rates in
patients with HRS are lower than in patients without
HRS.7
Use of a splanchnic arterial vasoconstrictor is associ-
ated with improvement in renal function in type 1
HRS.8-13 Terlipressin, a vasopressin derivative, is the
most widely used vasoconstrictor in Europe because of
its effectiveness and ease of administration4; and it
improves renal function in 40%-50% of patients.14-19
In countries such as the United States, where terlipres-
sin is not available, midodrine and octreotide with
albumin8 have been used in uncontrolled studies to
treat HRS, with reported reversal of HRS as high as
40%.20-22 Midodrine is an alpha1-adrenergic agonist
which causes splanchnic vasoconstriction. Octreotide, a
somatostatin analogue, enhances the splanchnic vaso-
constriction by inhibiting glucagon-mediated splanch-
nic vasodilatation. However, the combination of
midodrine and octreotide has not been compared with
terlipressin in the treatment of HRS. Therefore, the
aim of this study was to compare terlipressin plus
albumin versus midodrine and octreotide plus albumin
in the treatment of HRS in patients with cirrhosis.
Patients and Methods
Inclusion and Exclusion Criteria. After institu-
tional review board approval at each institution and
trial registration (NCT00742339), patients were
entered into the study following written informed con-
sent. The study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki.
Inclusion criteria included cirrhosis diagnosed by
liver biopsy or clinical, biochemical, ultrasound, and/
or endoscopic findings; type 1 or severe type 2 HRS as
defined by International Ascites Club criteria of serum
creatinine level >226 lmol/L (2.5 mg/dL)2,4; and age
18-75 years. Exclusion criteria were hepatocellular car-
cinoma outside Milan criteria,23 septic shock, cardiac
or respiratory failure, stroke, or coronary artery
disease.
Definitions of Response to Treatment. Complete
response was defined as a decrease in serum creatinine
to !133 lmol/L (!1.5 mg/dL). Partial response was
defined as a "50% serum creatinine decrease from
baseline to a final value >133 lmol/L (>1.5 mg/dL).
No response was defined as a serum creatinine decrease
of <50% from baseline.
Study Design. Diuretic agents were withheld, and
albumin (1 g/kg body weight) was infused intrave-
nously for 48 hours for plasma expansion in all eligible
patients.2,4 Patients who then met inclusion criteria
were entered into the study and randomized to receive
terlipressin plus albumin or midodrine and octreotide
plus albumin.
Patients were randomized at each hospital using
sealed opaque envelopes containing the treatment
assignments based on random numbers generated by
the Stata statistical package (version 7.0, 1999; Stata
Corp, College Station, TX). Patients with type 1 HRS
were randomized independently from those with type
2 HRS.
Demographic, clinical, and laboratory data; vital
signs; and Model for End-stage Liver Disease (MELD)
scores were recorded at the time of inclusion. Physical
examination, electrocardiogram, chest X-ray, and rou-
tine laboratory tests were performed in all patients at
regular intervals during treatment.
In all patients included in the study, albumin (Albu-
mina 20%; Kedrion S.p.A., Barga, Italy) was adminis-
tered intravenously, 1 g/kg at day 1 and 20-40 g/day
subsequently for the duration of the study.
In the TERLI group, terlipressin (Glypressin; Fer-
ring AB, Malm€o, Sweden) was administered initially at
a dose of 3 mg/24 hours by continuous intravenous
infusion. Response to treatment was evaluated every
48 hours. If serum creatinine decreased by <25% of
the pretreatment value, the dose of terlipressin was
progressively increased to 12 mg/24 hours. In patients
randomized to the MID/OCT group, midodrine
(Gutron; Lusofarmaco, Peschiera Borromeo, Italy) was
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administered orally at a starting dose of 7.5 mg every
8 hours along with octreotide (Longastatina; Italfar-
maco S.p.A., Milan, Italy) administered subcutaneously
at a starting dose of 100 lg every 8 hours. If serum
creatinine decreased by <25% of the pretreatment
value, the dose of midodrine was progressively
increased to a maximum of 12.5 mg every 8 hours
and octreotide to 200 lg every 8 hours. Terlipressin as
well as midodrine plus octreotide were administered
until serum creatinine decreased to !133 lmol/L
(1.5 mg/dL) or for a maximum of 14 days. Treatment
was maintained for 24 hours after a complete or incom-
plete response. Treatment was withheld if adverse effects
developed such as angina and/or arrhythmia, peripheral
ischemia, or severe abdominal pain.
Treating physicians were allowed to start any rescue
treatment in nonresponders. After discharge, patients
were followed for up to 3 months, liver transplanta-
tion, or death. For survival analysis patients were cen-
sored at the time of transplant.
Statistical Analysis. The primary endpoint of the
study was complete response at completion of treat-
ment, and this was used for sample size calculation.
Because terlipressin is a stronger splanchnic arterial
vasoconstrictor than midodrine, it was hypothesized
that complete recovery of renal function could occur
in 60% of patients treated with terlipressin and in
30% of those treated with midodrine plus octreotide.
Using a two-tailed test, 43 patients were required in
each group, for a P value <0.05 with an a error of
5% and a b error of 20%. An interim analysis was
provided after the enrollment of half of the sample
size, and a stopping rule for the randomized clinical
trial was fixed if the difference in recovery of renal
function was significant at P< 0.01. The interim
analysis was performed by an independent statistician.
Results are presented as mean6 standard deviation
for continuous data and proportions for categorical
ones. Group or subgroup comparisons were per-
formed using the Student t test or Wilcoxon rank
sum tests for continuous data and the chi-squared
test or Fisher’s exact test for categorical data. Survival
was estimated using the Kaplan-Meier method and
compared with the log-rank test. Variables that were
found to be predictors of response and of survival,
with P< 0.1 in the univariate analysis, were included
in a multivariate logistic regression model; and the
results were presented as odds ratios with a 95% con-
fidence interval. All tests were two-tailed. P< 0.05
was considered to be statistically significant. Statistical
analyses of the data were performed using SPSS 10
statistical software (SPSS Inc. and Microsoft Corp.,
Chicago, IL).
Results
Patients. The study was terminated after 49
patients were included according to the a priori deter-
mined stopping rule. A total of 66 patients with cir-
rhosis and HRS diagnosed between 2008 and 2012
in eight hospitals in Italy were evaluated for inclusion
in the study. Seventeen of the 66 patients screened
were excluded for reasons outlined in Fig. 1 (consort
diagram). The remaining 49 patients were randomly
assigned to one of the two treatment groups: 27 to
terlipressin plus albumin (TERLI group) and 22 to
midodrine and octreotide plus albumin (MID/OCT
group). One patient randomized in the MID/OCT
group was excluded from analysis of data because of
liver transplantation at day 2. A flowchart of patients
entered into the study and included in the analysis of
data is provided in Fig. 1.
There were no significant differences between the
two groups in clinical and laboratory data at the time
of enrollment (Table 1). No patient had alcoholic hep-
atitis. The two groups were also similar with respect to
the percentage of patients with type 1 HRS (93% in
the TERLI group versus 90% in the MID/OCT
group).
Reversal of Renal Failure. Improvement of renal
function was significantly more frequent in patients
randomized to the TERLI group than in patients
randomized to the MID/OCT group (Fig. 2): 19 of
27 patients in the TERLI group (70.4%) had a com-
plete or partial response compared with six of 21
(28.6%) in the MID/OCT group (P5 0.01); 15 of 27
patients in the TERLI group (55.5%) had a complete
response compared with one of 21 in the MID/OCT
group (4.8%) (P< 0.001). The reduction of serum
creatinine in all responders was higher in the TERLI
group (from 323.26 91.1 to 121.66 30.0 lmol/L,
3.66 1.0 to 1.36 0.3 mg/dL) than in the MID/OCT
group (from 332.86 85.1 to 159.86 15.9 lmol/L,
3.76 0.9 to 1.86 0.2 mg/dL), but the difference was
not statistically significant. The reduction of serum
creatinine in all patients in the TERLI group (from
326.86 88.4 lmol/L to 221.16 162.8 lmol/L) was
statistically higher than in the MID/OCT group (from
343.96 187.5 to 326.46 273.2 lmol/L; P5 0.035).
In the TERLI group 13 of the 15 complete responders
to treatment responded to 3 mg/day and two
responded to 6 mg/day. As far as the four partial
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responders are concerned, all received the maximal tol-
erated dose, which was 3 mg/day in one patient,
6 mg/day in one patient, and 12 mg/day in the
remaining two patients.
The only complete responder in the MID/OCT
group responded to 22.5 mg/day of midodrine plus
300 lg/day of octreotide. The five partial responders
in the MID/OCT group received the maximal
Table 1. Demographic, Clinical, and Laboratory Features at
Baseline in Patients Who Were Randomized to Terlipressin
Plus Albumin (TERLI Group) or to Midodrine and Octreotide
Plus Albumin (MID/OCT Group)
Parameter
TERLI Group
(n5 27)
MID/OCT Group
(n5 21) P
Age, years 606 12 656 10 NS
Male/female, n 21/6 11/10 NS
Etiology (viral/no viral), n 10/17 8/13 NS
HRS type 1/type 2 25/2 19/2 NS
HRS precipitated by
bacterial infections, Y/N
16/11 11/10 NS
MAP, mm Hg 76.86 10.0 75.26 8.1 NS
Heart rate, bpm 77.86 11.5 81.16 13.4 NS
International normalized ratio 2.06 0.5 1.76 0.5 NS
Serum bilirubin, mmol/L 201.16 268.3 187.86 252.4 NS
Serum bilirubin, mg/dl 11.76 15.6 10.96 14.6 NS
Serum creatinine, mmol/L 326.86 88.4 343.96 187.5 NS
Serum creatinine, mg/dL 3.66 1.0 3.86 2.1 NS
Serum sodium, mmol/L 130.86 5.5 133.56 7.7 NS
MELD 31.26 5.8 29.16 8.1 NS
MELD-Na 32.76 4.4 29.86 6.9 NS
Hemoglobin, g/dL 9.96 1.4 9.96 1.5 NS
Serum albumin, g/dL 30.86 3.6 31.86 7.0 NS
Serum urea, mmol/L 23.46 9.4 22.26 11.1 NS
Serum potassium, mmol/L 4.46 1.0 4.66 0.8 NS
Aspartate aminotransferase, U/L 89.06 73.8 68.66 54.6 NS
Alanine aminotransferase, U/L 43.76 24.6 34.96 31.5 NS
Gamma-glutamyl transferase, U/L 69.66 70.9 81.76 80.6 NS
Abbreviation: MELD-Na, Model for End-Stage Liver Disease and Serum Sodium
Concentration; NS, nonsignificant.
Fig. 2. Rates of response in patients who were randomized to terli-
pressin plus albumin (TERLI) or to midodrine and octreotide plus albu-
min (MID/OCT). Gray bars represent patients with complete or partial
response; white bars represent patients with complete response.
Fig. 1. Study flowchart.
Abbreviation: LT, liver
transplantation.
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tolerated dose, which was 37.5 mg/day of midodrine
plus 600 lg/day of octreotide in four patients and
22.5 mg/day of midodrine plus 300 lg/day of octreo-
tide in the remaining one patient.
There were no significant differences between the
two groups of patients with respect to the duration of
treatment (8.26 4.4 days in the TERLI group versus
9.16 5.0 days in the MID/OCT group;
P5nonsignificant) or the cumulative albumin dose
after the initial load (264.86 200.2 g versus
313.66 185.4 g; P5nonsignificant).
Mean arterial pressure (MAP) was significantly
higher in the TERLI group versus the MID/OCT
group after 3 days of treatment as well as at the mid-
point of the treatment period (Fig. 3).
Predictors of Reversal of HRS. In univariate anal-
ysis the presence of bacterial infection as a precipitat-
ing event of HRS, baseline MELD score, serum
creatinine, serum bilirubin, MAP, and delta MAP at
the third day of treatment were not found to be pre-
dictors of response to treatment (Table 2). In multivar-
iate analysis only delta MAP at the third day and
randomization (TERLI group versus MID/OCT
group) were included. The only independent predictor
of reversal of HRS was found to be randomization to
the TERLI group (hazard ratio5 6.3, 95% confidence
interval 1.6-24.4, P5 0.007).
Rescue Treatment. Some nonresponders to the
assigned treatment received a rescue treatment (if
they were still alive) according to the treating physi-
cian’s decision. Five nonresponders in the TERLI
group and three nonresponders in the MID/OCT
group died before any rescue treatment. One patient
out of three (33.3%) nonresponders in the TERLI
group received a rescue treatment with dialysis.
Seven of 12 (58.3%) nonresponders in the MID/
OCT group received a rescue treatment: six received
terlipressin plus albumin, and one received dialysis.
An improvement of renal function was observed in
five of six patients (83.3%) who received terlipressin
plus albumin, which was complete in four patients
and partial in one.
Survival. There were no significant differences
between the two groups with respect to number of
patients who were alive at 1 and 3 months: 19/27
(70%) and 16/27 (59%), respectively, in the TERLI
group, and 14/21 (67%) and 9/21 (43%), respectively,
in the MID/OCT group (P5nonsignificant). Res-
ponders to assigned treatment showed a better survival
than nonresponders (P< 0.001). Figure 4 shows the
cumulative survival of patients included in the study at
3 months classified according to response to random-
ized treatment, terlipressin plus albumin (left graph)
and midodrine and octreotide plus albumin (right
graph). The difference in cumulative survival between
all responders (partial and full responders) and nonres-
ponders was statistically significant in the TERLI
group (P< 0.001) but not in the MID/OCT group
(P5nonsignificant). Regarding the potential role of
rescue treatment in this discrepancy, a higher 3-month
survival rate in patients who did not receive any rescue
treatment in the TERLI group than in the MID/OCT
group was found (55.5% versus 28.6%, P5 0.06).
Finally, considering all the randomized patients as a
whole, a significant difference in cumulative survival at
3 months was observed when patients with a reduction
in serum creatinine "50% from baseline were com-
pared to patients with a reduction in serum creatinine
<50% from baseline (73.7% versus 37.9%, respec-
tively; P< 0.025).
Fig. 3. Mean arterial pressure (MAP) in patients who were randomized
to terlipressin plus albumin (TERLI group) or to midodrine and octreotide
plus albumin (MID/OCT group) during treatment. Gray bars represent MAP
in the TERLI group; white bars represent MAP in the MID/OCT group.
Table 2. Clinical and Laboratory Features of
Baseline Variables According to Response to Treatment
Parameter
Total Responders
(n5 25)
Nonresponders
(n5 23) P
Age, years 626 12 636 12 0.690
HRS precipitated by
bacterial infections, Y/N
16/9 11/12 0.383
MAP, mm Hg 77.56 9.8 74.56 8.2 0.267
Delta MAP at 3 days, mm Hg 6.26 8.7 1.56 13.1 0.097
Heart rate, bpm 78.46 11.2 80.66 13.9 0.576
International normalized ratio 2.06 0.6 1.86 0.4 0.183
Serum bilirubin,
mmol/L (mg/dL)
166.86 212.2
(9.76 12.3)
229.96 307.7
(13.36 17.8)
0.433
Serum creatinine,
mmol/L (mg/dL)
325.56 88.0
(3.66 1.0)
343.86 180.5
(3.86 2.0)
0.669
MELD 31.06 6.4 29.56 7.4 0.450
Serum albumin, g/dL 30.46 3.5 32.46 7.0 0.372
Randomization, TERLI group
versus MID/OCT group
19/6 8/15 0.008
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Predictors of Survival. Among all patients
entered into the study, only response (complete or par-
tial) to treatment was found to be a predictor of 3-
month survival in the univariate analysis (Table 3a). In
multivariate analysis, response to treatment and base-
line MELD score were predictors of 3-month survival
(Table 3b).
Adverse Events. We found no significant differen-
ces in adverse events supposed to be associated with
assigned treatment (Table 4). Adverse events led to dis-
continuation of treatment in one patient in the TERLI
group (stroke) and one patient in the MID/OCT group
(grade 4 bradycardia). The former died as a conse-
quence of stroke.
Discussion
On the basis of the large benefit in renal response
to terlipressin plus albumin compared with midodrine
and octreotide plus albumin, the study was terminated
after the interim analysis, according to the provided
stopping rule.
Improvement in renal function was associated with
a significant increase in arterial pressure in both
groups, confirming the existence of a major relation-
ship between circulatory and renal function in patients
with HRS.24-26 The greater effect of terlipressin treat-
ment on increasing MAP may explain the higher effi-
cacy of terlipressin plus albumin over midodrine and
octreotide plus albumin in improving renal function
(Fig. 3). Of importance, there were no differences in
adverse events between the groups.
The rate of renal response to midodrine (28.6%)
may be considered in the range of the results obtained
in clinical practice. Nevertheless, it was lower than the
response observed in a previous larger retrospective
study (40%).22 In order to explain this discrepancy, it
should be highlighted that in the retrospective study by
Esrailian et al.22 (1) the plasma volume expansion for
the diagnosis of type 1 HRS was performed also with
Fig. 4. Cumulative 3-month survival in patients who were randomized to terlipressin plus albumin (TERLI group) or to midodrine and octreotide
plus albumin (MID/OCT group) according to the response: solid line represents responders; dotted line represents nonresponders. Abbreviation:
N.S., nonsignificant.
Table 3a. Univariate Analysis of
Predictors for 3-Month Survival
Parameter Hazard Ratio 95% Confidence Interval P
Randomized treatment 0.52 0.16-1.64 0.26
Response to treatment 8.97 2.43-33.16 0.001
Baseline MELD 1.09 0.99-1.20 0.07
Table 3b. Multivariate Analysis of
Predictors for 3-Month Survival
Parameter Hazard Ratio 95% Confidence Interval P
Response to treatment 22.93 3.17-165.86 0.002
Baseline MELD 1.19 1.03-1.37 0.02
Table 4. Adverse Events Supposed to
Be Related to the Randomized Treatment
TERLI group
(n5 27)
MID/OCT group
(n5 21) P
Abdominal pain 2 (7.4%) 3 (14.3%) NS
Diarrhea 2 (7.4%) 0 NS
Arrhythmia 0 2 (9.5%) NS
Circulatory overload 1 (3.7%) 1 (4.8%) NS
Arterial hypertension 1 (3.7%) 0 NS
Stroke 1 (3.7%) 0 NS
Total 7 (25.9%) 6 (28.6%) NS
Adverse events led to discontinuation of assigned treatment in one patient in
the TERLI group and one patient in the MID/OCT group.
Abbreviation: NS, nonsignificant.
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saline alone; (2) more than 50% of treated patients had
alcoholic hepatitis, in whom recovery of renal function
could have occurred only as a result of the improve-
ment of their liver disease; (3) several patients with alco-
holic hepatitis were cotreated with pentoxyphylline; and
(4) the treatment with midodrine plus octreotide was
not found to be an independent predictor of renal
response. One may argue that the rate of complete
response in patients of the MID/OCT group was even
lower that that observed with albumin alone in the
study of Sanyal et al.17 With that in mind, in the pres-
ent study the rate of renal response was globally higher
than that observed in the study of Sanyal et al. (28.6%
versus 18%); again, it should be highlighted that in the
study of Sanyal et al. the plasma volume expansion for
the diagnosis of type 1 HRS was performed also with
saline alone and that 36% of included patients had
alcoholic hepatitis. On the other hand, the percentage
of patients with partial or complete renal response in
the group treated with terlipressin plus albumin appears
significantly higher than that found in two main previ-
ous controlled trials in terms of either complete
response (56% versus 33.9%-39%)15,17 or complete
and partial responses (70% versus 43.5%).15 We believe
that two factors may explain this difference in the rate
of response to terlipressin plus albumin. First, in the
two previous studies terlipressin was given by intrave-
nous bolus every 4 or 6 hours. This schedule may have
reduced the vasoconstrictor effect of terlipressin. In fact,
in a pharmacodynamic study performed in patients
with cirrhosis, the effect of terlipressin on portal pres-
sure was shown to last less than 4 hours.27 Therefore,
terlipressin was administered as a continuous intrave-
nous infusion in the current study. Second, according to
the diagnostic criteria of the International Club of Asci-
tes reported in 2007, patients with renal failure and
active bacterial infections are considered as having
HRS.4 Recent observations suggest that the rate of
response to terlipressin and albumin in patients with
infection related HRS is as high as 67%.28
For ethical reasons, a rescue treatment was provided
in nonresponders to randomized treatment, including
the possibility of crossing over from one study drug
regimen to the other. Thus, it is necessary to point out
that the study design was not ideal for evaluating the
effect of the randomized treatment on the secondary
endpoint, which was survival at 1 and 3 months. The
"intention to treat" survival at 1 and 3 months was
not significantly different in the two groups.
Nevertheless, the results of the study allowed us to
make some observations on survival. First, the response
to treatment was found to be an independent predictor
of survival. Second, the difference in 1-month and 3-
month survival between responders and nonresponders
was greater in the TERLI group (Fig. 4, left panel)
than in the MID/OCT group (Fig. 4, right panel). A
great impact of rescue treatment on renal function and/
or survival in nonresponders in the MID/OCT group
should be considered in order to explain this difference.
Thus, 3-month survival was higher in the TERLI group
than in the MID/OCT group when only patients who
did not receive any rescue treatment were considered.
As far as adverse events are concerned, despite the
greater vasoconstrictor effect of terlipressin, serious
adverse events and/or adverse events that led to treat-
ment discontinuation were not significantly different in
the two groups. Nevertheless, stroke and arterial hyper-
tension were observed only in patients who were treated
with terlipressin. Circulatory overload and arrhythmia
could be related also to factors other than the vasocon-
strictor effect, such as renal failure per se and/or electro-
lyte imbalance.
In conclusion, the results of this randomized, com-
parative study indicate that administration of terlipres-
sin plus albumin is more effective in improving both
renal function and survival in patients with cirrhosis
and HRS compared with midodrine and octreotide
plus albumin. Thus, terlipressin plus albumin should
currently be considered the first choice for manage-
ment of patients with cirrhosis and HRS.
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